原能生物启动B轮融资 正筹备科创板上市

Core Insights - The company, Shanghai Yuaneng Cell Biology Low-Temperature Equipment Co., Ltd., has initiated a Series B financing round with a pre-investment valuation of approximately 1.8 billion RMB [1] - The company is preparing for an independent listing on the Sci-Tech Innovation Board, believing it meets the recently reinstated fifth set of listing standards [1] - The fifth set of standards focuses on "market value + R&D" rather than revenue and profit, requiring a minimum market value of 4 billion RMB and significant technological advantages [1] Company Overview - Yuaneng Bio specializes in the research, design, and manufacturing of advanced automated low-temperature storage equipment for cell biology [2] - The company serves clients including top-tier hospitals, disease control centers, biopharmaceutical companies, and germplasm centers [2] - The traditional cell storage equipment has limitations such as inefficiency, frost formation, cross-contamination, exposure to room temperature, and traceability issues, which Yuaneng aims to address with its automated solutions [2] Financial and Market Strategy - The company has a strong order backlog and aims to double its revenue next year [3] - The chairman indicated that the company is close to filing for the Sci-Tech Innovation Board, with the only remaining hurdle being revenue size [3] - The current financing round is intended to be the last before the company communicates with the exchange and undergoes restructuring to expedite its listing process [3]